Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor target genes in human colorectal cancer cells

Carcinogenesis

Volumn 23, Issue 1, 2002, Pages 107-114

  Hawcroft, Gillian ^a   D'Amico, Mark ^b   Albanese, Chris ^b   Markham, Alexander F ^b   Pestell, Richard G ^b   Hull, Mark A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; INDOMETACIN; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PLAKOGLOBIN; T CELL FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE G1 PHASE; COLORECTAL CANCER; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ACETYLCYSTEINE; BETA CATENIN; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; CYCLIN D1; CYTOSKELETAL PROTEINS; DESMOPLAKINS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GAMMA CATENIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOMETHACIN; INTERLEUKIN-2; ISOENZYMES; NITROBENZENES; PROMOTER REGIONS (GENETICS); PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SULFONAMIDES; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0036199569     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Prostaglandin H synthases, non-steroidal anti-inflammatory drugs and colon cancer
2. Min/+ mice
3. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis
4. Influence of indomethacin and difluoromethylornithine on human tumour growth in nude mice
5. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
6. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
7. Malignant transformation and anti-neoplastic actions of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclooxgenase-null embryo fibroblasts
8. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
9. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells
10. PPARδ is an APC-regulated target of non-steroidal anti-inflammatory drugs
11. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action
12. Control of β-catenin signalling in tumor development
13. Differential molecular interactions of β-catenin and plakoglobin in adhesion, signalling and cancer
14. The Yin-Yang of TCF/β-catenin signalling
15. Molecular determinants of dysplasia in colorectal lesions
16. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
17. Identification of c-MYC as a target of the APC pathway
18. Gastrin is a target of the β-catenin/TCF-4 growth-signalling pathway in a model of intestinal polyposis
19. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors
20. Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC
21. γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin
22. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene
23. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
24. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
25. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling
26. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin
27. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated β-catenin
28. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation
29. Inhibition of β-catenin translocation-a novel explanation for the protective effect of non-steroidal drugs in colorectal cancer
30. Sulindac sulphone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
31. Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice
32. Identification of four distinct pools of catenins in mammalian cells and transformation-dependent changes in catenin distributions among these pools
33. Overexpression of protein kinase C-β1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells
34. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells
35. The c-myc protein is consitutively expressed at elevated levels in colorectal carcinoma cell lines
36. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells
37. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc
38. Bax is a transcriptional target and mediator of c-Myc-induced apoptosis
39. Role of BAX in the apoptotic response to anti-cancer agents
40. WISP-1 is a Wnt-1 and β-catenin responsive oncogene
41. Inhibition of cellular proliferation through IκB kinase-independent and PPARγ receptor dependent repression of cyclin D1
42. Ester and amide dervatives of the non-steroidal anti-inflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors
43. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal anti-inflammatory drugs to potent and highly selective COX-2 inhibitors